Solid Form Selection in Preclinical Drug Development

Join us for a free one-hour webinar exploring pharmaceutical solid form selection. Become familiar with the various elements used to optimize the solid state form of drug candidates.

Date and Time:
June 23, 2009 1:00 pm, Eastern Daylight Time (New York, GMT-04:00)

Introduction

Selection of a suitable solid form for a new development candidate is a critical step in preclinical drug development. This presentation discusses the processes and criteria typically employed when selecting an optimal solid state form. The selection process generally begins in-silico with the prediction of basic properties of the API (logP, pKas, solubility, rule of 5, etc). This information is used to design salt and/or co-crystal screening studies aimed at optimizing the solid state and biopharmaceutical properties, taking into account the intended use and route of administration of the drug. After completing the salt and/or co-crystal screen, the best salt or co-crystal candidates are commonly assessed for polymorphism, in-vivo availability, processability, and formulation development. Following appropriate selection criteria, this process leads to an optimized solid state form of the drug candidate.

Topics to be covered

• Introduction to Solid Forms
• Salt Screening and Selection
• Co-crystals
• Polymorph Screening
• Processability
• Bioavailability